Option Care Health Inc OPCH 深 滬
已收盤 02-06 16:00:00 美东时间
34.00
-0.170
-0.50%
華盛通- 最 高34.635
- 今 開34.24
- 成交量 162.58万股
- 最 低 33.72
- 昨 收 34.17
- 總市值 53.97亿
- 52周最高 36.80
- 市盈率 靜 27.74
- 換手率 1.02%
- 52周最低 24.235
- 委 比 30.86%
- 總股本 1.59亿
- 歷史最高 70.48
- 量 比 1.23
- 振 幅 2.68%
- 歷史最低 3.92
- 每 手 1
- 風險率 2.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Option Care Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call
Option Care Health Inc. announced the release of its fourth quarter and full year 2025 financial results on February 24, 2026, before market open. The management team will host a conference call at 8:30 a.m. E.T. the same day. Participants can pre-register via the provided link or access the live audio webcast at investors.optioncarehealth.com. A replay will be available shortly after the call for up to 90 days. Option Care Health is the largest ...
01-21 21:05
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Option Care Health Reports Q4 Preliminary Adjusted EPS Of $0.46 - $0.49, Net Revenue Of $1.46B - $1.47B; FY25 Adjusted EPS Of $1.72 - $1.76, Net Revenue Of $5.645B - $5.655B; Expects FY26 Adjusted EPS Range $1.82 To $1.92, Net Revenue Range $5.8B To $6B
Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today preliminary unaudited financial
01-13 05:38
Option Care Health Announces Preliminary Fourth Quarter & Full Year 2025 Financial Results and Preliminary Financial Guidance for Full Year 2026
Option Care Health announced its preliminary financial results for Q4 and FY 2025, forecast FY 2026 guidance, and expanded its share repurchase program to $1.0 billion. The company reported net revenue of $5.645-$5.655 billion for FY 2025, with adjusted diluted EPS of $1.72-$1.76. For FY 2026, it expects net revenue of $5.8-$6.0 billion and adjusted diluted EPS of $1.82-$1.92. The expanded share repurchase program, with no expiration, allows repu...
01-12 21:35
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
2025-12-18 21:04
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Deutsche Bank Maintains Buy on Option Care Health, Raises Price Target to $36
Deutsche Bank analyst Pito Chickering maintains Option Care Health (NASDAQ:OPCH) with a Buy and raises the price target from $31 to $36.
2025-12-10 01:03
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
